EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Midori Shima iD, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita

Haemophilia · 2026

DOI: 10.1111/hae.70162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Midori Shima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Product Surveillance, Postmarketing. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018.

Aim

To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who initiated emicizumab within 1 year of availability.

Methods

This all‐case post‐marketing surveillance (PMS) study was conducted between May 2018 and January 2023, in patients of all ages and HA severities. Patients were registered retrospectively after emicizumab initiation or prospectively at the time of initiation. Adverse events (AEs) and adverse drug reactions (ADRs), including thromboembolic events (TEs) and thrombotic microangiopathy (TMA), and their association with BPA use, were examined. FVIII inhibitor levels and annualised bleeding rates (ABRs) were evaluated.

Results

In total, 134 patients were included in the analysis. Mean (standard deviation) duration of emicizumab treatment was 145.5 (34.8) weeks. Overall, 112 AEs occurred in 47 patients (35.1%) and 22 ADRs occurred in 12 patients (9.0%); 8 ADRs (36.4%) were serious. No TEs/TMAs associated with concomitant use of BPAs occurred. FVIII inhibitor levels remained stable or decreased for 34 patients (55.7%). Sixty‐eight patients (50.7%) received BPAs; none received activated prothrombin complex concentrate. Mean (95% confidence interval) model‐based all bleed ABR and treated bleed ABR were 1.4 (0.9–2.3) and 1.3 (0.8–2.1), respectively.

Conclusion

This study comprises 3 years’ PMS for emicizumab. No TEs/TMA associated with BPAs occurred. Results further support the safety and effectiveness of emicizumab in Japanese patients with congenital HA with inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, BispecificAntibodies, Monoclonal, HumanizedProduct Surveillance, PostmarketingHumansMaleAdultJapanChildAdolescentFemaleYoung AdultChild, PreschoolMiddle AgedRetrospective StudiesInfantTreatment OutcomeFactor VIIIEast Asian People

Stichwörter der Autor:innen

Japanemicizumabhaemophilia Apost‐marketingproduct surveillance

Substanzen

emicizumabAntibodies, BispecificAntibodies, Monoclonal, HumanizedFactor VIII

Autor:innen und Institutionen

  • Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan.
  • Department of Pediatrics, Nara Medical University, Kashihara, Japan.
  • Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan.
  • Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.
  • Department of Hematology, Nara Medical University, Kashihara, Japan.
  • Drug Safety Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.

ORCID-Profile: Midori Shima

Förderung

  • Chugai Pharmaceutical Co., Ltd

Zitieren

APA

Shima, M., Fukutake, K., Matsumoto, M., Sugimura, Y., Sugita, C., Ji, L., Kawano, M., & Matsushita, T. (2026). Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors. Haemophilia. https://doi.org/10.1111/hae.70162

Vancouver

Shima M, Fukutake K, Matsumoto M, Sugimura Y, Sugita C, Ji L, et al. Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors. Haemophilia. 2026. doi:10.1111/hae.70162

BibTeX
@article{Shima2026,
  author = {Shima, Midori and Fukutake, Katsuyuki and Matsumoto, Masanori and Sugimura, Yoshihiko and Sugita, Chiaki and Ji, Lyu and Kawano, Mika and Matsushita, Tadashi},
  title = {Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70162}
}
Kostenlos starten →